Allergic rhinitis, also known as hay fever, is a common condition that affects millions of people worldwide. It is caused by an allergic reaction to allergens such as pollen, dust mites, animal dander, and mold. Symptoms of allergic rhinitis include sneezing, runny nose, nasal congestion, itching, and watery eyes. The global allergic rhinitis drugs market is expected to grow significantly in the coming years due to the increasing prevalence of allergic rhinitis and the availability of advanced treatment options.
According to a report by ResearchAndMarkets, the global allergic rhinitis drugs market is expected to grow at a CAGR of 3.94% from 2021 to 2026. The report also states that the market was valued at $10.56 billion in 2020 and is expected to reach $13.39 billion by 2026. The increasing prevalence of allergic rhinitis, the availability of advanced treatment options, and the rising demand for over-the-counter (OTC) drugs are some of the key factors driving the growth of the market.
One of the major trends in the global allergic rhinitis drugs market is the increasing adoption of immunotherapy. Immunotherapy is a treatment that involves exposing the patient to small doses of allergens over a period of time. This helps the patient’s immune system to become less sensitive to the allergens, thus reducing the severity of allergic reactions. Immunotherapy is becoming increasingly popular as it is a long-term solution for allergic rhinitis and can provide lasting relief from symptoms.
Another trend in the market is the availability of OTC drugs for allergic rhinitis. OTC drugs are drugs that can be purchased without a prescription. They are usually used for the treatment of mild to moderate symptoms. The availability of OTC drugs is increasing as they are more convenient for patients and can help reduce healthcare costs.
The global allergic rhinitis drugs market is also expected to benefit from the development of new drugs. Many pharmaceutical companies are investing in research and development to develop new and more effective drugs for the treatment of allergic rhinitis. For example, in 2021, Sanofi announced that it had received approval from the European Commission for its new drug, Nasacort Allergy 24HR. The drug is a nasal spray that provides 24-hour relief from allergic rhinitis symptoms.
In conclusion, the global allergic rhinitis drugs market is expected to grow significantly in the coming years due to the increasing prevalence of allergic rhinitis, the availability of advanced treatment options, and the rising demand for OTC drugs. The market is also expected to benefit from the increasing adoption of immunotherapy and the development of new drugs. With the increasing focus on healthcare and the growing awareness about allergic rhinitis, the market is poised for strong growth in the future.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Brite View Research journalist was involved in the writing and production of this article.